The CSL Ltd (ASX: CSL) share price has edged 1.48% lower since this time last week.
While the global biotech hasn’t released any market sensitive news in that time, investors have been offloading the company’s shares.
CSL shares closed a further 0.73% down on Monday at $273.15 each.
What’s weighing down CSL shares lately?
A couple of factors are playing against CSL shares for the moment as the COVID-19 pandemic begins to subside.
First and foremost, the S&P/ASX 200 Health Care index (ASX: XHJ) has reversed its gains over the past week, down 0.3%. The index closed another 0.16% lower today.
Investors appear to have focused their efforts on better performing ASX sectors such as the S&P/ASX 300 Metals & Mining (ASX: XMM) index. This consists of the top 300 ASX companies that are involved with gold, steel, and precious metals.
For context, the Metals & Mining sector has soared 5.96% from this time last Monday.
And it’s no surprise that commodity prices have skyrocketed, given the war in Ukraine and inflationary movements.
Market psychology can be a powerful force when crowd behaviour chases market rallies or selloffs during downturns.
Another factor that has led CSL shares to fall is the delay to complete the acquisition of Vifor Pharma.
Originally, the deal was due to be wrapped up by June 2022. However, receiving regulatory approvals is taking a little longer.
As such, CSL now expects the takeover to be finalised within the next few months.
CSL share price snapshot
Uncharacteristically, it has been a turbulent year for CSL shareholders, recording a loss of 4% over the last 12 months.
Year to date has not fared any better with the company’s shares down 6%.
Based on valuation grounds, CSL commands a market capitalisation of roughly $131.5 billion.
The post Why has the CSL share price lagged the ASX 200 over the past week? appeared first on The Motley Fool Australia.
Should you invest $1,000 in CSL right now?
Before you consider CSL, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and CSL wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of January 13th 2022
More reading
- 2 top blue chip ASX 200 shares to buy now according to experts
- Why I would invest $10,000 into these ASX shares today
- Is the Telstra share price cheap compared to other ASX 200 shares?
- Why CSL shares are ‘going to deliver’ in 2022: fund manager
- ‘Future-proof your portfolio’: experts pick 3 quality growth ASX shares to buy
Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
from The Motley Fool Australia https://ift.tt/0UkGZnS
Leave a Reply